Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy

Myeloid-derived suppressor cells (MDSCs) promote immune evasion, a key feature of oncogenesis. The restoration of immunosurveillance by immunomodulatory antibodies improves the survival of a subset of cancer patients. Preclinical studies suggest that the ablation of monocytic MDSCs may be a useful a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lesokhin, Alexander M., Merghoub, Taha, Wolchok, Jedd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601158/
https://www.ncbi.nlm.nih.gov/pubmed/23525353
http://dx.doi.org/10.4161/onci.22764
_version_ 1782475726753103872
author Lesokhin, Alexander M.
Merghoub, Taha
Wolchok, Jedd D.
author_facet Lesokhin, Alexander M.
Merghoub, Taha
Wolchok, Jedd D.
author_sort Lesokhin, Alexander M.
collection PubMed
description Myeloid-derived suppressor cells (MDSCs) promote immune evasion, a key feature of oncogenesis. The restoration of immunosurveillance by immunomodulatory antibodies improves the survival of a subset of cancer patients. Preclinical studies suggest that the ablation of monocytic MDSCs may be a useful adjunct to available immunotherapeutic strategies against cancer.
format Online
Article
Text
id pubmed-3601158
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36011582013-03-22 Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy Lesokhin, Alexander M. Merghoub, Taha Wolchok, Jedd D. Oncoimmunology Author's View Myeloid-derived suppressor cells (MDSCs) promote immune evasion, a key feature of oncogenesis. The restoration of immunosurveillance by immunomodulatory antibodies improves the survival of a subset of cancer patients. Preclinical studies suggest that the ablation of monocytic MDSCs may be a useful adjunct to available immunotherapeutic strategies against cancer. Landes Bioscience 2013-02-01 /pmc/articles/PMC3601158/ /pubmed/23525353 http://dx.doi.org/10.4161/onci.22764 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Lesokhin, Alexander M.
Merghoub, Taha
Wolchok, Jedd D.
Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
title Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
title_full Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
title_fullStr Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
title_full_unstemmed Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
title_short Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
title_sort myeloid-derived suppressor cells and the efficacy of cd8(+) t-cell immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601158/
https://www.ncbi.nlm.nih.gov/pubmed/23525353
http://dx.doi.org/10.4161/onci.22764
work_keys_str_mv AT lesokhinalexanderm myeloidderivedsuppressorcellsandtheefficacyofcd8tcellimmunotherapy
AT merghoubtaha myeloidderivedsuppressorcellsandtheefficacyofcd8tcellimmunotherapy
AT wolchokjeddd myeloidderivedsuppressorcellsandtheefficacyofcd8tcellimmunotherapy

Ejemplares similares